Dr. Jacobs Discusses the Frontline Treatment of CLL

Ryan W. Jacobs, MD
Published: Tuesday, May 15, 2018



Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia (CLL).

Currently, the only small molecule inhibitor approved for the frontline treatment of patients with CLL is ibrutinib (Imbruvica). The approval of ibrutinib in this setting was based on data from the RESONATE-2 trial.

The use of novel treatments in the frontline setting is limited to chemoimmunotherapy and ibrutinib, Jacobs says, but the combination of these 2 therapies has shown promise. In a phase II study presented at the 2017 ASH Annual Meeting, ibrutinib combined with fludarabine-cyclophosphamide-rituximab chemoimmunotherapy demonstrated an objective response rate of 100%, including a complete response rate of 40% with or without hematologic recovery.

When choosing frontline treatment for patients, it is important to consider the available data, Jacobs says. Head-to-head data with novel agents in the frontline setting are not yet available. Until then, Jacobs says that the best thing to do is subgroup analyses and cross-trial comparisons.


Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia (CLL).

Currently, the only small molecule inhibitor approved for the frontline treatment of patients with CLL is ibrutinib (Imbruvica). The approval of ibrutinib in this setting was based on data from the RESONATE-2 trial.

The use of novel treatments in the frontline setting is limited to chemoimmunotherapy and ibrutinib, Jacobs says, but the combination of these 2 therapies has shown promise. In a phase II study presented at the 2017 ASH Annual Meeting, ibrutinib combined with fludarabine-cyclophosphamide-rituximab chemoimmunotherapy demonstrated an objective response rate of 100%, including a complete response rate of 40% with or without hematologic recovery.

When choosing frontline treatment for patients, it is important to consider the available data, Jacobs says. Head-to-head data with novel agents in the frontline setting are not yet available. Until then, Jacobs says that the best thing to do is subgroup analyses and cross-trial comparisons.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x